CDEK
← All drugs Report issue

iopamidol

Trade name: Isovue

Small moleculeapproved

Approved

Dec 31, 1985

Iopamidol is a nonionic, low-osmolar iodinated contrast agent. Iopamidol is indicated for angiography, pediatric angiocardiography, selective visceral arteriography and aortography, peripheral venography, and adult and pediatric intravenous excretory urography and intravenous adult and pediatric contrast enhancement of computed tomographic. Renal toxicity has been reported in a few patients with liver dysfunction who were given oral cholecystographic agents followed by intravascular contrast agents. Intravascular injection of contrast media is frequently associated with the sensation of warmth and pain especially in peripheral arteriography and venography. In angiocardiography the adverse reactions are: hot flashes, angina pectoris, flushing, bradycardia, hypotension, hives. — NCATS

Clinical trial activity

31 trials · 26 clinical orgs · 9 marketing orgs

Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
21

Earliest trial started Feb 1, 2004 (NCT02170688)

Timeline

1980s

  1. Dec 31, 1985

    Bracco — Earliest FDA Approval

  2. Dec 31, 1985

    Bracco — NDA Secondary Org

  3. Dec 31, 1985

    Bracco — NDA Organization

1990s

  1. Nov 6, 1996

    Baxalta — Marketing Organization

  2. Nov 6, 1996

    Baxter — Marketing Organization

  3. Apr 2, 1997

    Fresenius — Marketing Organization

  4. Apr 3, 1997

    Hospira — Marketing Organization

  5. Apr 30, 1997

    AbbVie — Marketing Organization

2000s

  1. Jul 28, 2000

    Cook Medical — Marketing Organization

  2. Jan 1, 2007

    Bracco — Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2008

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jun 18, 2010

    Sanochemia Corp — Marketing Organization

  2. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Feb 27, 2023

    Hainan Poly Pharm — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetOTHER

    Diagnostic agent

  • contrast mediumRadiopaque

    contrast medium radiopaque

Approval history

  • approvedDec 31, 1985

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I
Mol. weight
777.0853 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • iopamidol
  • iopamidol
  • iopamidol
  • iopamidol
  • iopamidol
  • iopamidol
  • iopamidol
  • iopamidol
  • iopamidol
  • iopamidol
  • iopamidol-200
  • iopamidol-200
  • iopamidol-250
  • iopamidol-250
  • iopamidol-300
  • iopamidol-300
  • iopamidol-370
  • iopamidol-370
  • iopamiron
  • isovue
  • isovue
  • isovue
  • isovue-128
  • isovue-128
  • isovue-200
  • isovue-200
  • isovue-200
  • isovue-250
  • isovue-250
  • isovue-300
  • isovue-300
  • isovue-370
  • isovue-370
  • isovue-m 200
  • isovue-m 200
  • isovue-m 200
  • isovue-m 300
  • isovue-m 300
  • scanlux-300
  • scanlux-300
  • scanlux-370
  • scanlux-370
  • sq-13396
  • sq-13396

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06411795Phase 2Nov 10, 2023National Cancer Institute (NCI), University of Minnesota
NCT05489055N/AFeb 1, 2022Chongqing Medical University, People's Liberation Army of China
NCT05031520N/AJul 12, 2021New York University
NCT04870645N/AMar 30, 2021National Cancer Institute (NCI), University of Texas at Houston
NCT04504331Phase 1Oct 13, 2020National Cancer Institute (NCI), QED Therapeutics, Inc., Stanford University
NCT03779906Phase 4Feb 1, 2019Bracco
NCT03557385Phase 4Jul 31, 2018Acist Medical Systems, Duke University
NCT03384979Phase 4Dec 18, 2017University of Milan
NCT03071328Early Phase 1 (Phase 1)Jul 1, 2017Duke University
NCT02433665N/AAug 1, 2015Duke University, Nemoto Kyorindo Co, Ltd.
NCT02467075Phase 4Jul 1, 2015Radiological Society of North America, University of Michigan
NCT02291718Phase 4Jan 1, 2014Duke University
NCT01672996Phase 1/Phase 2 (Phase 2)Jul 1, 2012General Electric, IQVIA
NCT02040285Phase 4Feb 1, 2012University of Roma La Sapienza
NCT01475097Phase 4Oct 1, 2011General Electric, Optum
NCT01376089Phase 4May 1, 2011General Electric, Optum
NCT01137786Phase 4Dec 1, 2010Bracco
NCT01136915Phase 4Nov 1, 2010Bracco
NCT01136876Phase 4Nov 1, 2010Bracco
NCT01075217Phase 4Apr 1, 2010Bracco
Showing 20 of 31 trials
Page 1 / 2

Organizations

Research & Development (26)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BraccoFor profit121222004
Duke UniversityAcademic/Hospital6642004
General ElectricFor profit4422005
National Cancer Institute (NCI)Government3032020
IQVIAFor profit2022005
OptumFor profit2012011
People's Liberation Army of ChinaGovernment2022008
ABX-CROFor profit1012005
Acist Medical SystemsFor profit1012018
Aptiv SolutionsFor profit1012005
Chongqing Medical UniversityAcademic/Hospital1112022
CovanceFor profit1012005
Examination Management Services Inc.For profit1012005
Nemoto Kyorindo Co, Ltd.For profit1012015
New York UniversityAcademic/Hospital1112021
QED Therapeutics, Inc.For profit1012020
Radiological Society of North AmericaAcademic/Hospital1012015
Shantou UniversityAcademic/Hospital1112008
Southern Medical UniversityAcademic/Hospital1012008
Stanford UniversityAcademic/Hospital1112020
26 organizations
Page 1 / 2

Marketing (11)

OrganizationOrg typeRelationshipDate
AbbVieFor profitMKTGApr 30, 1997
BaxaltaFor profitMKTGNov 6, 1996
BaxterFor profitMKTGNov 6, 1996
BraccoFor profitNDA2Dec 31, 1985
BraccoFor profitNDADec 31, 1985
Cook MedicalFor profitMKTGJul 28, 2000
FreseniusFor profitMKTGApr 2, 1997
Hainan Poly PharmFor profitMKTGFeb 27, 2023
Hainan Poly PharmFor profitSYNSep 27, 2023
HospiraFor profitMKTGApr 3, 1997
Sanochemia CorpFor profitMKTGJun 18, 2010